BDH Industries Ltd

BDH Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggests a more attractive price point for investors amid a challenging market backdrop and strong long-term returns.

BDH Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

BDH Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

BDH Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

BDH Industries, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation, reflecting nuanced shifts across key financial and technical parameters. This adjustment highlights evolving perspectives on the company’s quality, valuation, financial trends, and technical outlook amid a backdrop of mixed performance indicators.

BDH Industries Ltd is experiencing notable selling pressure, with a five-day decline resulting in a significant loss. The stock has underperformed compared to the Sensex, showing a stark contrast in weekly and monthly performance. Recent trends suggest a shift in market sentiment, impacting its moving averages.

BDH Industries Ltd is experiencing significant selling pressure, marking its fourth consecutive day of losses with a total decline of 12.55%. The stock has underperformed against the Sensex over various time frames, reflecting a shift in market sentiment amid challenges in the pharmaceuticals and biotechnology sector.

BDH Industries Ltd is experiencing notable selling pressure, with the stock declining over the past three days and underperforming against the Sensex. Despite strong long-term gains, recent trends show a shift in market sentiment, as the stock struggles below certain moving averages amid a challenging environment.

BDH Industries Ltd., a Mumbai-based pharmaceutical manufacturer with a market capitalisation of ₹254.00 crores, reported a net profit of ₹0.69 crores for the quarter ended March 2016, representing a decline of 25.94% quarter-on-quarter from ₹12.18 crores. The micro-cap pharmaceutical company, which specialises in antibiotic, anti-inflammatory, and anti-microbial therapeutic formulations, saw its stock trading at ₹454.50 as of November 14, 2025, reflecting modest gains of 0.33% in the immediate aftermath of the results. Despite the quarterly setback, the company maintains a strong balance sheet with zero debt and healthy operating margins of 9.48%.

BDH Industries Ltd is experiencing strong buying activity, outperforming the broader market. The stock has gained significantly over the past week and months, consistently trading above key moving averages. This performance may be influenced by positive market sentiment and developments in the pharmaceuticals and biotechnology sector.

BDH Industries Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity, with a significant rise in its stock today. Despite recent challenges, the company has shown strong long-term growth, outperforming the Sensex over various time frames, including a substantial increase over five years.